Kura Oncology Announces Global Strategic Collaboration With Kyowa Kirin
November 22, 2024
November 22, 2024
PALO ALTO, California, Nov. 22 -- Cooley, a law firm, issued the following news release:
San Diego - November 20, 2024 - Cooley advised clinical-stage biopharmaceutical company Kura Oncology (Nasdaq: KURA) on its global strategic collaboration with Kyowa Kirin to develop and commercialize ziftomenib, Kura's selective oral menin inhibitor that is being investigated for the treatment of acute myeloid leukemia (AML) and other hematologic malignancies.
Under the terms . . .
San Diego - November 20, 2024 - Cooley advised clinical-stage biopharmaceutical company Kura Oncology (Nasdaq: KURA) on its global strategic collaboration with Kyowa Kirin to develop and commercialize ziftomenib, Kura's selective oral menin inhibitor that is being investigated for the treatment of acute myeloid leukemia (AML) and other hematologic malignancies.
Under the terms . . .